Ignite Creation Date:
2024-05-06 @ 2:36 PM
Last Modification Date:
2024-10-26 @ 1:33 PM
Study NCT ID:
NCT04364230
Status:
COMPLETED
Last Update Posted:
2023-10-11
First Post:
2020-04-21
Brief Title:
Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma Including Ocular Melanoma
Sponsor:
Craig L Slingluff Jr
Organization:
University of Virginia
Study Overview
Official Title:
Enhanced Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists in Patients With Melanoma
Status:
COMPLETED
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Mel66
Brief Summary:
This study evaluates whether it is safe to administer a peptide vaccine made of 6MHP and a mutated neoantigen peptide BRAF585-614-V600E combined with adjuvants The adjuvants that will be used in this trial are a CD40 antibody CDX-1140 and a toll-like receptor TLR 3 agonist Poly-ICLC The study will also investigate the effects of the vaccine and the adjuvants on the immune response The investigators will monitor these effects by performing tests in the laboratory on participants blood and skin tissue
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None